3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
7
Lung Neoplasms
4
Neoplasm Metastasis
2
Triple Negative Breast Neoplasms
1
Rectal Neoplasms
1
Neoplasms
1
Intestinal Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Ductal
1
Carcinoma
1
Breast Neoplasms
1
Adenocarcinoma of Lung
1
Adenocarcinoma
1
Interventions
pembrolizumab
48
Carboplatin
34
Pemetrexed
28
Cisplatin
25
Docetaxel
23
Nivolumab
21
Paclitaxel
20
Gemcitabine
15
Magnetic Resonance Spectroscopy
14
Specimen Handling
12
Radiotherapy
12
Cyclophosphamide
12
Radiosurgery
11
130-nm albumin-bound paclitaxel
11
Erlotinib Hydrochloride
10
Bevacizumab
10
osimertinib
9
Cetuximab
8
Temozolomide
7
Taxes
7
Ipilimumab
7
Biopsy
7
fludarabine
6
Ramucirumab
6
Radiation
6
veliparib
5
tislelizumab
5
durvalumab
5
cemiplimab
5
atezolizumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasm Metastasis
×
canakinumab
×
Thoracic
×
Clear all
NCT03631199
2026-02-25
CANOPY-1
Novartis
Phase 3
Terminated
673 enrolled
38 charts
NCT03626545
2023-08-21
CANOPY-2
Novartis
Phase 3
Terminated
245 enrolled
29 charts